Fig. 7

Knockdown PES1 sensitizes cancer cells to anti-PD1 therapy. A The representative image of subcutaneous tumors in indicated treatments. B, C Tumor volume over time B (Additional file 5: Dataset S4) and tumor weight C for AKR tumor-bearing mice (n = 4 mice per group). *p < 0.05. D HE and IHC were performed to examine the tumor area and detect the expression of CD3, CD8, and GZMB (Additional file 5: Dataset S4). (E–G) The CD3 + T cells (E), CD8 + T cells (F), GZMB + CD8 + T cells G were quantified (n = 4). Data shown as mean ± SD, statistical analysis by t test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. H Western blotting exhibits the expression of PES1 and IL15 from pre-treatment tumors of pCR and non-pCR patients with ESCC. pCR: pathological complete response; non-pCR: non-pathological complete response. I The representative IHC images of PES1, IL15 and CD8 from pre-treatment tumors of pCR (n = 5) and non-pCR (n = 5) patients and were quantified. Scale bar = 100 μm. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. J Representative PLA images detecting the interaction between endogenous PES1 and ILF3 in pre-treatment pCR and non-pCR tissues. Scale bar = 100 μm